Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-11-29
pubmed:abstractText
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-10069510, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-10764302, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-11316667, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-11865999, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-11866001, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-11871363, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-12114338, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-15218994, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-15764761, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-15774995, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-16387952, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-16507855, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-17703327, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-1951400, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-2145136, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-2879458, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-3118746, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-3530643, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-3538958, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-5914258, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-6230249, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-7886652, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-8441331, http://linkedlifedata.com/resource/pubmed/commentcorrection/18044064-8681667
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1176-9106
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
33-40
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
The development of anticholinergics in the management of COPD.
pubmed:affiliation
University Hospitals of Leicester Glenfield Site, Institute for Lung Health, Leicester, UK. jane.scullion@uhl-tr.nhs.uk
pubmed:publicationType
Journal Article, Review